Genentech CEO Ashley Magargee: The expanded investment allows Genentech to build out additional production capacity and significantly increase the facility's output. Set to be operational by 2029, the state-of-the-art facility will produce next- generation treatments for metabolic conditions, such as obesity. By leveraging advanced biomanufacturing, automation, and digital tools, the investment will boost efficiency and sustainability while significantly expanding Genentech's U.S.-based supply chain. The ex ...